# CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy

> **NCT00257205** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 655 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** dacarbazine
- **DRUG:** CP-675,206
- **DRUG:** temozolomide

## Key facts

- **NCT ID:** NCT00257205
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-03
- **Primary completion:** 2010-08
- **Final completion:** 2010-08
- **Target enrollment:** 655 (ACTUAL)
- **Last updated:** 2012-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00257205

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00257205, "CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00257205. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*